荷兰结直肠癌筛查项目分阶段实施后晚期结直肠癌发病率模式
该研究基于荷兰癌症登记处2010-2019年数据,按邀请队列分析晚期结直肠癌发病率。2014年首次受邀筛查的队列在筛查引入前发病率从94.1升至124.7/10万,2014年升至184.9/10万,随后降至低于筛查前趋势的预期水平。后续邀请队列呈现相似模式,2014-2016邀请队列累积晚期结直肠癌发病率显著低于预期。
要点
- 2014年首次受邀筛查队列晚期结直肠癌发病率在筛查引入前从94.1升至124.7/10万,2014年升至184.9/10万。
- 此后发病率降至低于基于筛查前趋势的预期水平,后续邀请队列呈现相似模式。
- 2014-2016邀请队列累积晚期结直肠癌发病率显著低于2010-2019年期间预期累积发病率。
核心结论
- 2014-2019年期间,所有首次受邀筛查的邀请队列均观察到晚期结直肠癌发病率升高,随后降至低于预期水平,符合分阶段实施模式。
- 多次受邀筛查的邀请队列累积晚期结直肠癌发病率低于基于筛查前趋势的预期值,这些发现支持荷兰筛查项目引入与晚期结直肠癌发病率下降之间的因果关系。
研究设计与样本
- 通过荷兰癌症登记处收集2010-2019年期间按邀请队列分组的晚期结直肠癌发病率数据。
- 计算晚期结直肠癌粗发病率和累积发病率,并与基于筛查引入前数据外推趋势线得到的预期发病率进行比较。
主要发现
- 2014年首次受邀筛查的队列,晚期结直肠癌发病率在筛查引入前从2010年的94.1/10万升至2013年的124.7/10万。
- 2014年观察到发病率升至184.9/10万,高于之前年份的增幅,此后降至低于基于筛查前趋势的预期发病率水平。
- 后续年份的邀请队列呈现相似模式,与首次受邀筛查时间相吻合,2019年所有邀请队列的观察发病率仍低于预期发病率。
- 2014-2016邀请队列的累积晚期结直肠癌发病率显著低于2010-2019年期间的预期累积发病率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: From 2014, the Dutch colorectal cancer (CRC) faecal immunochemical testing-based screening programme was gradually rolled out by birth cohort. We evaluated changes in advanced-stage CRC incidence by timing of invitation to further strengthen the evidence for the effectiveness of CRC screening. METHODS: Data on advanced-stage CRC incidence in the period 2010-2019 by invitation cohort were collected through the Netherlands Cancer Registry. Crude rates of advanced-stage CRC incidence and cumulative advanced-stage CRC incidence were calculated. Observed advanced-stage CRC incidence and cumulative advanced-stage CRC incidence were compared with expected advanced-stage CRC incidence and cumulative advanced-stage CRC incidence by invitation cohort using trend lines extrapolating data prior to the introduction of screening. RESULTS: For the invitation cohort that was first invited for screening in 2014, advanced-stage CRC incidence increased before the introduction of screening from 94.1 to 124.7 per 100,000 individuals in the period 2010-2013. In 2014, the observed increase was higher than in preceding years, to 184.9 per 100,000 individuals. Hereafter, a decrease in incidence was observed to levels below expected incidence based on trends before the introduction of screening. A similar pattern was observed for invitation cohorts in subsequent years, coinciding with the first invitation to the screening programme. In 2019, the observed incidence for all invitation cohorts remained below expected incidence. The cumulative advanced-stage CRC incidence in the 2014-2016 invitation cohorts was significantly lower than the expected cumulative CRC incidence in the period 2010-2019. CONCLUSIONS: In the period 2014-2019, an increase in advanced-stage CRC incidence was observed for all invitation cohorts first invited for screening, followed by a decrease below expected incidence, following the pattern of the phased implementation. The cumulative advanced-stage CRC incidence in invitation cohorts invited for screening multiple times was lower than expected based on trends from the pre-screening era. These findings support a causal relationship between the introduction of the Dutch screening programme and a decrease in advanced-stage CRC incidence.
引用
- Breekveldt ECH, Toes-Zoutendijk E, Spaander MCW, et al. Advanced-stage CRC incidence patterns following the phased implementation of the CRC screening programme in the Netherlands. Eur J Cancer. 2022. PMID: 36403368. doi:10.1016/j.ejca.2022.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。